As of November 6, 2026, Cullinan Therapeutics Inc is a publicly traded company (Nasdaq: CGEM); its largest reported holder is BVF Partners, with 9.99% on Schedule 13G/A of August 14, 2026, then LYNX1 Capital Management LP (9.8%) (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Cullinan Therapeutics Inc? See the free Snapshot first.
Free to see. No signup.
Is Cullinan Therapeutics Inc a real, registered company?
- Cullinan Therapeutics Inc files with the SEC under CIK 1789972 (its SEC filings).
- Its shares are listed under the ticker CGEM on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Cullinan Therapeutics Inc in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names T. Rowe Price (filed 2026-08-14).
Who are Cullinan Therapeutics Inc's owners and officers?
Cullinan Therapeutics Inc: incorporated in Delaware; business address in Cambridge, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | T. Rowe Price Associates, Inc. | 6.2% |
| Schedule 13G/A, 2026-08-14 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 6% |
| Schedule 13G/A, 2026-05-15 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G, 2026-03-04 | Kynam Capital Management, LP | 5.27% |
| Schedule 13G/A, 2026-02-17 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G, 2026-01-30 | The Vanguard Group | 5.58% |
| Schedule 13G/A, 2025-11-14 | Lynx1 Capital Management LP | 9.8% |
| Schedule 13G/A, 2025-11-14 | Kenneth Griffin | 3.4% |
| Schedule 13G/A, 2025-11-13 | Deerfield Mgmt, L.P. | 4.95% |
| Schedule 13G/A, 2025-10-30 | The Vanguard Group | 4.98% |
Questions about who owns Cullinan Therapeutics Inc
Who owns Cullinan Therapeutics Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Cullinan Therapeutics Inc: Bvf Partners L P/Il (9.99%, Schedule 13G/A, filed 2026-08-14), Lynx1 Capital Management LP (9.8%, Schedule 13G/A, filed 2025-11-14), T. Rowe Price Associates, Inc. (6.2%, Schedule 13G, filed 2026-08-14), State Street Corporation (6%, Schedule 13G, filed 2026-08-07) and Kynam Capital Management, LP (5.27%, Schedule 13G, filed 2026-03-04).
Who are the largest shareholders of Cullinan Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Cullinan Therapeutics Inc on this page are Bvf Partners L P/Il (9.99%), Lynx1 Capital Management LP (9.8%) and T. Rowe Price Associates, Inc. (6.2%).
When did Bvf Partners L P/Il buy into Cullinan Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Bvf Partners L P/Il on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Cullinan Therapeutics Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cullinan Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cullinan Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Cullinan Therapeutics Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 8,963,500 shares (13.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-30).
- Lynx1 Capital Management LP, a 10% owner: 8,963,500 shares (13.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-30).
- , the chief executive and president: 390,803 shares (0.61% of shares outstanding) (Form 4, 2026-02-25).
- , the chief business officer: 240,990 shares (0.37% of shares outstanding) (Form 4, 2025-02-21).
- , the chief medical officer: 159,968 shares (0.25% of shares outstanding) (Form 4, 2026-02-25).
Shares outstanding: 64,354,694 as of 2026-07-31, from the company's latest SEC cover page.
How much has Cullinan Therapeutics Inc raised?
No fundraising or offering filing from Cullinan Therapeutics Inc is on file with us.
Keep reading
More on Cullinan Therapeutics Inc and the records around it.
Cullinan Therapeutics Inc elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/cullinan-therapeutics